Summary & Overview
HCPCS C9022: Injection, elosulfase alfa, 1 mg
HCPCS Level II code C9022 denotes the administration of elosulfase alfa, billed per 1 mg of the biologic injection. Elosulfase alfa is an enzyme replacement therapy used in the management of mucopolysaccharidosis IVA (Morquio A), and its billing as a HCPCS Level II code reflects high-cost, specialty biologic infusions that are typically delivered in outpatient infusion centers or hospital outpatient settings. Nationally, accurate coding for high-cost biologics like elosulfase alfa is critical for coverage determinations, reimbursement accuracy, and utilization monitoring.
Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of what the code represents, typical sites of service, and the clinical context for use. The publication provides benchmarks and payer coverage considerations, highlights policy and coding updates relevant to specialty biologics, and outlines related billing themes such as unit-based dosing and infusion service lines. This summary is intended for billing managers, revenue cycle leaders, and clinicians involved in specialty infusion therapy administration who need clear, national-level context for HCPCS Level II code C9022.
Billing Code Overview
HCPCS Level II code C9022 represents the injection of elosulfase alfa, 1 mg, an enzyme replacement therapy used to treat patients with mucopolysaccharidosis IVA (Morquio A syndrome). The service type is therapeutic biologic injection administered intravenously. The typical site of service is an infusion center or hospital outpatient infusion clinic, where the medication is delivered under monitored conditions due to its biologic nature and potential for infusion reactions.
Service line: Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A pediatric or adult patient with confirmed mucopolysaccharidosis type IVA (Morquio A syndrome) presents for enzyme replacement therapy with elosulfase alfa. The patient arrives at an outpatient infusion center or hospital outpatient clinic for a scheduled intravenous infusion. Pre-infusion assessment includes vital signs, review of recent labs and cardiac/respiratory status, and allergy history. An infusion nurse verifies the medication C9022 (injection, elosulfase alfa, 1mg) dose based on patient weight and prepares the dose under aseptic technique. Premedication (e.g., antihistamine, antipyretic) is given per protocol when indicated. The infusion is administered via peripheral IV or implanted port over the recommended infusion time with continuous monitoring for infusion-related reactions. Post-infusion observation occurs for a period determined by institutional protocol; documentation captures drug lot number, dose administered in mg, infusion start and stop times, any administered premedications, patient tolerance, and discharge instructions. Typical sites of service are outpatient infusion centers, hospital outpatient departments, and specialized metabolic clinics. Payors involved commonly include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare for eligible patients.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services |